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This article is a shortened version of a report 
entitled “The Future of Academic Medicine: Five 
Scenarios to 2025” [1] published by the Milbank 
Memorial Fund (www.milbank.org). A summary 
of this article is being published in the BMJ. 
Introduction
“Academic medicine” might be deﬁ ned 
as the capacity of the health-care system 
to think, study, research, discover, 
evaluate, innovate, teach, learn, and 
improve. As such, little could be 
more important—particularly as new 
discoveries in science offer tremendous 
opportunities and emergent diseases 
pose huge threats. Yet something is not 
right with academic medicine. Worse, 
the diagnosis is not entirely clear, 
although many august bodies have 
reported on the issue (Table 1), and 
the treatment is unknown. Moreover, 
these previous consultations have 
been based in the industrialised world, 
particularly the United Kingdom and 
the United States, and few have taken a 
global view.
The International Campaign 
to Revitalise Academic Medicine 
(ICRAM) was founded to give young 
medical academics an opportunity to 
think about the future of academic 
medicine (Box 1). It started with only 
two premises: (1) at the start of the new 
millennium it was necessary to think 
globally, and (2) “more of the same” 
was not the answer. Reinvention was 
needed. 
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Box 1. ICRAM
In 2003 the BMJ, Lancet, and 40 
other partners launched ICRAM, a 
global initiative that is committed to 
fostering a debate about the future 
of academic medicine (http://bmj.
com/academicmedicine). The campaign 
arose because of a persistent concern 
that academic medicine is in crisis 
around the world. At a time of increasing 
health burden, poverty, globalisation, 
and innovation, many have argued that 
academic medicine is nevertheless failing 
to realise its potential and global social 
responsibility. 
ICRAM is composed of the following:
• A core working party of 20 medical 
academics representing 14 countries
• Stakeholder groups representing 
the areas of academia, business and 
industry, government and policy makers, 
journal editors, patients, professional 
associations, and students and trainees
• Regional groups covering the world
• A facilitating committee that helps plan 
and execute the ICRAM work
Through a series of stakeholder and 
regional consultations, systematic review 
of the available evidence, and future 
scenarios building, ICRAM intends to 
produce a series of recommendations 
for reform in global academic medicine, 
including the following:
• Developing a vision and values for 
academic medicine 
• Recommending strategies for building 
capacity in academic medicine, including 
better career paths
• Proposing how academic medicine 
could improve its relationships with 
“customers,” including patients, policy 
makers, practitioners, and others
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ICRAM decided to undertake some 
scenario planning, a technique of 
thinking about both the future and 
the present. The technique works 
by gathering together a team who 
consider the instabilities in the present 
and the drivers of the future and who 
then imagine plausible but different 
futures. The aim is not to predict the 
future, which is impossible, but to 
enable richer conversations through 
stretching thinking on what the future 
might bring. Once the scenarios have 
been created, they can be used to think 
more deeply about the present and the 
near future.
The group began by considering 
current instabilities in academic 
medicine around the world (Box 2). 
None of these ideas are new, and most 
people would probably agree with most 
of them. 
Much of what determines the future 
of academic medicine will lie outside 
the control of medical academics 
themselves. The world will change 
around them, and they will have to 
follow. But there will also be change 
that comes from within academic 
medicine. Box 3 shows some of the 
drivers of the future considered by the 
group.
Five Scenarios
In building scenarios, the group used 
a time span of 20 years, but some of 
the scenarios are more futuristic than 
others. We decided to write up the 
scenarios as if they were in the past 
in order to give some idea of how 
they might arise. The scenarios are 
summarised in Table 2, and described 
more fully in the rest of this article. 
Academic Inc.: “Academic medicine 
ﬂ ourishes in the private sector”. Slowly 
but surely the public sector around the 
world realised that it could not support 
the costs of academic medicine. 
Medical students had high earnings 
during a professional lifetime: why 
shouldn’t they pay for their education? 
And if researchers were doing 
something valuable then shouldn’t 
they be able to ﬁ nd a market for their 
product—accepting that sometimes 
payment would come from the public 
sector?
The process of academic medicine 
moving almost entirely into the private 
sector began with an increasing 
number of medical schools becoming 
private. The most prestigious schools 
went ﬁ rst. In an increasingly global 
market these schools could charge 
high fees, pay their staff well, and 
improve their facilities. They also 
invested a great deal in information 
and communication technology, 
bringing state-of-the-art learning to 
their students. This meant too that the 
schools could run courses for students 
far away from their geographical 
Table 1. Reports of Major National Academic Medicine Organisations 
Country Reference Organisation and Report Title Date of Publication Challenges Identiﬁ ed
United Kingdom 3 Academy of Medical Sciences. “Clinical 
Academic Medicine in Jeopardy: 
Recommendations for Change.”
June 2002 “Prolonged training, early ﬁ nancial disincentives, 
tensions between the responsibilities for teaching, 
research and clinical service, are all deterrents to 
pursuing a clinical academic career. There is a need to 
promote academic medicine and make it once more an 
attractive career.”
4 Academy of Medical Sciences. 
“Strengthening Clinical Research.” 
October 2003 “Put simply, clinical research has not kept pace with 
the advances in basic scientiﬁ c discovery and this 
disadvantages patients.”
5 Royal College of Physicians. “Clinical 
Academic Medicine: The Way Forward.” 
November 2004 “The key aim must be to recruit and retain more clinical 
academic staff, by making the academic career path a 
more attractive and achievable option.”
6 Association of Academic Health Centers, 
Association of Canadian Medical Colleges, 
and the Nufﬁ eld Trust. “The Challenge to 
Academic Medicine: Leading or Following?” 
September 2002 “If they were to have credibility, academic medical 
centres need to have their own houses in order, in 
terms of transparency in the way funds are handled, 
and to be able to give a proper account of the value 
of their work to individuals, the population and the 
economy.” 
United States 7 Commonwealth Fund Task Force on 
Academic Heath Centers. “Envisioning the 
Future of Academic Health Centers.” 
February 2003 “Try as it might, the Task Force found it difﬁ cult to 
imagine how the United States could maximize the 
health of its citizenry without institutions resembling 
academic health centers. It seems inefﬁ cient at best, 
and foolhardy at worst, to dismantle the infrastructure 
that [academic health centers] have developed 
without ﬁ rst ﬁ rmly establishing the advantages of any 
alternative approach to pursuing their missions.”
8 Institute of Medicine of the National 
Academies. “Academic Health Centers: 
Leading Change in the 21st Century.” 
2004 “In taking on the [future] challenges, [academic health 
centers] will need to recognize the interdependent 
and complementary nature of their traditionally 
independent roles within an overall context that 
encompasses a commitment to improving the health 
of patients and populations.”
9 American Association of Medical Colleges. 
“Educating Doctors to Provide High 
Quality Medical Care: A Vision for Medical 
Education in the United States.” 
July 2004 “The shortcomings that exist in the ways doctors 
are educated must be remedied if the quality of the 
medical care provided in this country is to improve.”
DOI: 10.1371/journal.pmed.0020207.t001
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base. As these schools developed they 
expanded internationally, sometimes 
forming alliances with other prestigious 
schools but also taking over weaker 
schools. Soon the best schools were 
operating on all ﬁ ve continents. In 
the branches in developing countries, 
medical student bodies tended to 
comprise both students from the 
developed countries along with a quota 
from the developing countries. 
Competition was intense and involved 
both cost and quality. Schools that 
managed to improve quality while 
reducing costs—usually through 
clever use of technology—ﬂ ourished, 
but a great many medical schools 
disappeared. The numbers of students, 
however, increased, and the competition 
for talent was intense, with schools 
offering generous bursaries to poor but 
bright students and becoming ever more 
sophisticated at ﬁ nding high-quality 
students in resource-poor populations.
As happens in most intensely 
competitive markets, medical schools 
also competed by occupying niches. 
Schools offered very different kinds 
of courses, specialising in older 
students, basic science, rural medicine, 
surgical skills, training doctors for 
poor communities (in both the 
country where the medical school was 
based and lower and middle income 
countries), and many other subject 
areas. Sometimes the students’ fees 
were paid by governments, local 
communities, or the military in order 
to produce students who met their 
needs. Many students attended schools 
in countries other than their own.
Health research happened almost 
entirely in the private sector, but 
in a wide range of organisations: 
pharmaceutical companies, medical 
schools, biotechnology companies, 
small companies offering a huge range 
of services, and charities. Companies 
were founded not only by researchers 
but also by patients, practitioners, 
and others. Many of the companies 
founded by academics offered complex 
and innovative heath services. As in all 
business, to be successful companies 
had to be highly responsive to the 
needs of customers, including patients 
and governments. Those that were 
innovative, ﬂ exible, responsive, and 
relentlessly cost-conscious ﬂ ourished, 
but many companies “failed”. Little 
stigma was, however, attached to 
“failure”. Indeed, as in Silicon Valley at 
the end of the 20th century, experience 
of “failure” was seen by many as an 
important qualiﬁ cation in a leader.
The injection of more competitive 
pressure and a competitive business 
model into academic medicine 
increased not only efﬁ ciency but also 
“effectiveness”: research was much 
more relevant, and the time lag 
between the development of new ideas 
and their introduction into practice 
was dramatically shortened. Basic 
science was still well funded because 
both governments and investors 
recognised the potentially high returns. 
Research into the health needs of 
poor and marginal populations also 
improved because public sector bodies 
concentrated their resources into these 
problems, leaving the problems of the 
wealthier to the market.
Applying a competitive business 
model to academic medicine meant 
that efﬁ ciency and effectiveness 
trumped equity. On the negative 
side, the scenario “Academic Inc.” 
resulted in a two-tier system, with 
the rich ﬁ nding it easy to create 
careers in academic medicine and 
the poor ﬁ nding it hard to enter the 
profession—despite the generous 
bursaries available to some. In addition, 
much more attention continued to 
be paid to the health problems of 
wealthier people and countries, and 
the brain drain from poor to rich 
countries accelerated. Innovation also 
suffered. Private academic medicine 
enjoyed less lead time and had more 
direct and immediate accountability 
to its shareholders than when it was 
publicly funded. 
Box 2. Current Instabilities 
in Academic Medicine
• Widespread, even universal, agreement 
that things are not right but little 
agreement on the exact nature of the 
problem
• Lack of capacity in “translational 
research”—that which brings innovations 
directly to patients
• The substantial gap between best, 
evidence-based practice and what 
actually happens
• The canyon between academics and 
practitioners
• The growing difﬁ culty/impossibility of 
a single individual being competent in 
practice, research, and teaching
• Use of citation indices in research 
assessment, which overemphasises 
the value of basic research and 
underemphasises the importance of 
applied research that may bring more 
immediate beneﬁ t to patients
• A lack of mutual respect among 
different categories of researchers—
basic, clinical, public health, primary care, 
applied, etc.
• Problems with career progression for 
academics
• Shortages of doctors wanting to enter 
careers in research
• In many, probably most, countries those 
doctors who enter careers in research, 
who ideally would be the “best and the 
brightest,” being likely to earn much less 
than those who can spend at least some 
time working in private practice 
• Research often not being concerned 
with the biggest health problems 
(particularly true in a global context)
• Systems of accreditation of doctors 
making life difﬁ cult for doctors who want 
to pursue an academic career
• Although no clinicians are openly 
against research, clinicians being 
often unimpressed with doctors who 
concentrate on research
• Too much medical research being 
undertaken by doctors with limited 
training in research methods—making 
the research of poor quality
• Researchers often setting little store by 
quality improvement projects, although 
such projects are one of the ways of 
ensuring that all patients receive the 
most up-to-date care
• Much of the teaching in medicine being 
done by people with very little training in 
medicine
• The ratio of teachers to students in 
many medical schools being so low that 
the quality of teaching is reduced
• In many countries academic medicine 
lacking a well-resourced institution to 
speak for it
• Academic medicine relating poorly to 
its stakeholders—patients, policy makers, 
practitioners, the public, and the media
• The great pressures on health services, 
such that academic medicine is often 
squeezed and forgotten
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Reformation: “All teach, learn, 
research, and improve”. Twenty years 
ago there was increasing concern about 
the gap between academic medicine 
and practice, with important research 
results not being implemented, too 
much irrelevant research, bored 
students, and practitioners who 
stopped learning. In some medical 
communities and among their medical 
leadership, the response was not to try 
and strengthen academic medicine 
and make it more responsive but 
rather to abolish it and instead to bring 
the processes of teaching, learning, 
researching, and improving into the 
main stream of health care, and tailor 
these to local needs. This innovative—
though not initially welcomed—
response proved to be highly successful 
and was copied everywhere. A century 
of separation of academic medicine 
from practice was ended. Professors 
disappeared. The entity “academic 
medicine” was dead. It was akin to the 
destruction of the monasteries and so 
became known as the reformation of 
academic medicine.
Teaching, learning, researching, and 
quality improvement all began to take 
place in the practice setting and were 
everybody’s business. But importantly 
the ﬁ ction that an individual could 
be competent in practice, teaching, 
research, and improvement ﬁ nished. 
It was teams that had to have all these 
competencies not individuals, and 
substantial investment was made in 
getting teams to work well and to 
communicate to a degree rarely seen 
before in health care. 
The teams were supported by 
advanced technology that provided 
online learning, decision support, 
answers to questions that arose during 
practice, and access to research results. 
Much of the teaching and research was 
done in collaboration with patients, 
and all teams included patients as well 
as practitioners, students, professional 
researchers, and other health 
professionals.
Research was built around the 
questions that arose when doctors 
(and other health professionals) 
and patients consulted together. 
The questions were collected by the 
National Question Answering Service, 
which provided evidence-based answers 
to questions when it could. The service 
also organised research to answer 
questions that arose commonly, were 
unanswered at that time, but could 
be answered. Teams of different sizes 
and skills were assembled to conduct 
research; some of the researchers were 
permanently in practice but others—
particularly basic researchers—were 
resident in research institutions and 
joined teams as needed.
Some research was driven by 
discoveries made in basic science 
rather than questions that arose during 
practice; the fact that practitioners 
and researchers were used to 
working together in teams facilitated 
“translational” research.
The teams also switched back 
and forth from research to quality 
improvement, ensuring that research 
developments were fed through into 
practice. Studies reporting the results 
of quality improvement projects 
were published just as frequently 
Table 2. Summary of Scenarios
Characteristic Scenario
Academic Inc. Reformation In the Public Eye Global Academic 
Partnership
Fully Engaged
Description Academic medicine 
ﬂ ourishes in the private 
sector
All teach, learn, research, 
and improve
Success comes from 
delighting patients, the 
public, and media
Academic medicine for global 
health equity
Academic medicine engages 
energetically with all 
stakeholders
Main features Medical research, 




disappears; research and 
education integrated 
with health care 
Extreme consumerism; 
patients govern academic 
medicine; continual use of 
media
Global cooperative networks 
devoted to redressing health 
inequalities and 10:90 gap
Strong connections among 
patients, policy makers, 
practitioners, and the public
Medical education Private medical schools; 
major investment 
in information and 
communication 
technology; some niche 
schools (care of the elderly, 
rural medicine, etc.)
Team work; learning 
by doing; competency-
based assessment
Conducted by expert 
patients; responsiveness to 
patients is key value
Centred around improving 
global health; partnerships 
between medical schools in 
developed and developing 
countries
Medical training is energised 
and community-based; 
students help drive the 
agenda
Research Privatised, takes place 
in an array of different 
companies; responsive to 
the needs of customers





Patients determine priorities, 
through game shows or 
citizens’ juries
Public health and basic 
science equally valued
Conducted by groups of 
diversely skilled individuals, 
including stakeholders 
Decision making and 
governance
Corporate governance Leadership provided by 
societies of practitioners 
and patients
Bottom up: patients in 
charge
Global governance made 
up of institutional networks, 
policy makers, politicians, and 
the public
Dynamic organisations of 
all stakeholders to guide 
academic medicine
Disadvantages Efﬁ ciency and 
effectiveness trump 
equity; two tier system—
brain drain and 10:90 gap 
preserved; innovation may 
suffer
Lacks stability because 
requires shared values; 
decision making could 
be slow; individuals 
sometimes could not 
shine
Advances in science and 
technology subject to fads 
and fashion; job insecurity 
among practitioners; 
little regulation of health 
information 
Idealistic; requires enormous 
political will and global 
cooperation
Academic medicine may 
be perceived as “dumbed 
down”; may lose elite status, 
originality, and independent 
thinking 
DOI: 10.1371/journal.pmed.0020207.t002
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as research studies, and highly 
efﬁ cient information systems ensured 
that relevant information reached 
practitioners quickly—unlike in the 
old days when practitioners had been 
deluged with research results, most of 
which were irrelevant to them.
Intellectual leadership in health care 
was provided by specialist societies, 
which included patients, citizen juries, 
researchers, health professionals other 
than doctors, health managers, and 
policy makers as equal members. In 
most countries the specialist societies 
were gathered together into an 
academy or institute of health care, and 
there was an international academy 
that was much more than a talking 
shop: it had a strong inﬂ uence on 
world leaders.
Health students started their 
training with six months in institutions 
that taught them how to learn. The 
learning professionals who staffed 
these institutions were available to 
all the practice teams. Students then 
learnt through attachment to practice 
teams, starting with a spell in general 
practice. Some students specialised 
early, some becoming competent 
cardiologists within ﬁ ve years. 
Becoming an independent professional 
depended not on university degrees 
or exams but on a demonstration of 
competencies determined by a national 
body dominated by patients that 
used the most up-to-date methods for 
assessment.
Learning was by doing, and 
the divisions of undergraduate, 
specialist, and continuing education 
disappeared—as did the divisions 
among teaching, learning, researching, 
and quality improvement.
One problem with the “Reformation” 
scenario was that it lacked stability 
because it required shared values and 
beliefs, which not all teams held. Plus 
decision making could be slow, and it 
was hard for brilliant and charismatic 
individuals to shine as leaders and 
thinkers. One result was that such 
individuals eschewed careers in health 
care, research, and education. In 
developing countries, in particular, 
the lack of an academic medicine 
structure meant that there were fewer 
opportunities to inﬂ uence medical 
research and training. 
In the public eye: “Success comes 
from delighting patients and the 
public”. Academic medicine was slow 
to recognise the rise of global media, 
“celebrity culture,” and the use of 
public relations (or spin) to drive 
the political process, but once it did 
recognise how the world had changed 
it responded dramatically. Whereas it 
had been suspicious of the media and 
public appeal and rather patronising to 
patients, academic medicine realised 
that to succeed it must delight patients 
and the public and learn to use the 
media. The most successful academics 
became those who were very responsive 
to patients and the public, capturing 
their imaginations, and appearing 
regularly on their television screens. 
Some medical academics became as 
well known as ﬁ lm and rock stars and 
were feted by politicians.
All academic institutions became 
dominated by public citizens and 
patients, and the public and media 
relations department became the 
most important department in any 
institution. Money—from both 
public and private sources—followed 
“interest,” which was often inﬂ uenced 
through game and “reality” shows 
on television. Academic medicine 
learnt from sport, and large prizes 
were awarded to those who won 
academic competitions. Although some 
academics were horriﬁ ed by these 
developments, others remembered how 
John Harrison had been stimulated 
to solve the problem of calculating 
longitude through the promise of a 
large prize. 
Not all decisions on research 
priorities and resource allocation 
were made in the glare of television 
cameras. Although all decisions put 
the public interest ﬁ rst and were made 
by the representatives of the public, 
some were made by more sedate and 
evidence-driven bodies like citizens’ 
juries, where randomly selected 
patients and members of the public 
were presented with detailed evidence 
by “experts.”
Medical training was also conducted 
in the public eye, with students 
receiving much of their training 
from expert patients. The agenda for 
training was set predominantly by the 
public and patients, and responsiveness 
to patients was the number one 
characteristic of successful doctors and 
students.
There was much greater diversity 
than at the beginning of the 
millennium in the form and size 
of academic institutions, with both 
huge public and private universities 
and smaller institutions that were 
often built around one charismatic 
individual. Competition among the 
institutions was intense—particularly 
for “celebrity” teachers and researchers. 
Only those institutions that could 
attract and keep public attention could 
survive.
In developing countries, the 
academic health community linked 
itself with strong consumer movements, 
such as those focused on HIV/AIDS, 
and the leading nongovernmental 
organisations established their own 
medical schools. These ensured a 
powerful public voice, that training was 
tailored to local need, and a committed 
group for ﬁ eld testing new research 
advances.
On the negative side in the “In 
the Public Eye” scenario, medical 
academics felt more anxious about 
Box 3. Drivers of Change 
in Academic Medicine
• New science and technology, 
particularly genetics and information 
technology
• The rise of sophisticated consumers
• Globalisation
• Emergent diseases
• Increasing gap between rich and poor
• Death of distance
• “Big hungry buyers” demanding more 
from health care
• Spread of the internet and digitalisation
• Managerialism
• Increasing anxieties about security
• Expanding gap between what could be 
done and what can be afforded in health 
care
• Lack of agreement on where “health” 
begins and ends
• Ageing of society
• Feminisation of medicine
• Increasing accountability of all 
institutions
• Loss of respect for experts
• Rise of self care
• Rise of ethical issues
• 24/7 society
• Economic and political rise of India and 
China
July 2005  |  Volume 2  |  Issue 7  |  e207
PLoS Medicine  |  www.plosmedicine.org 0611
their job security and ability to succeed. 
Even celebrity academics worried their 
time in the spotlight was short lived. 
Advances in science, medicine, and 
technology were shaped by popular 
appeal, and thus subject to fads and 
fashion. Some patients struggled with 
their new-found status as governors, 
and there was little regulation of health 
information.
Global academic partnership: 
“Academic medicine for global health 
equity”. In 2005, the world began to 
ﬁ nd the growing global gap between 
the rich and poor unacceptable. The 
concern was driven partly by the media 
and global travel bringing the plight 
of the poor in front of the eyes of the 
rich, but it was also driven by anxieties 
over global security. Terrorism was 
recognised to be fuelled by the gap 
between rich and poor. Global policy 
makers also understood better—
particularly after the report of the 
Commission on Macroeconomics and 
Health [2]—that investment in health 
produced some of the richest returns 
in not only social but also economic 
development. Health care was a “must 
have” not a “nice to have”.
Money ﬂ owed into health in the 
poor world, and governments required 
that the investment be accompanied 
by learning, research, planning, and 
evaluation. The primary concern 
of much of academic medicine 
became to improve global health, 
particularly through concentrating 
on the health problems of the 90% 
who had previously received only 10% 
of health care resources (the 90:10 
gap). Academics became excited by 
this kind of work not only because it 
was intellectually exciting and highly 
rewarding in personal terms but also 
because it was where money and 
prestige were most likely to be found. 
The result was that it was impossible for 
an academic institution to be a world 
leader without a substantial investment 
in global health and extensive links 
around the world.
The view and scope of academic 
medicine broadened. It was 
increasingly concerned with human 
rights, justice, economics, and the 
environment, recognising that these 
are the major drivers of health. This 
broader view meant that academic 
medicine (usually referred to as “global 
health innovation” by 2012) became 
the main institution concerned with 
the rights of those who will be alive 50 
years from now, a group that previously 
had nobody to speak for them. But at 
the same time basic science remained 
important because of the contribution 
it could make to global problems like 
ﬁ nding vaccines and new treatments 
for malaria, AIDS, and emergent 
diseases like rapidly spread respiratory 
virus, which appeared in 2010 and 
killed millions in a global pandemic. 
Academic medicine, in partnership 
with governments (and where 
corruption is prevalent, with 
nongovernmental organisations), 
became a major driver towards 
achieving the millennium development 
goals. The G8 governments had signed 
an accord that prohibited recruitment 
of academic health professionals from 
developing countries. Medical schools 
and research institutions formed 
themselves into networks linking with 
local nongovernmental organisations, 
joining developed and developing 
countries and forming links among 
developing countries. A network was 
formed whereby the universities in 
developed countries committed 10% 
of their faculty members’ time to 
addressing problems of the developing 
world. Some institutions formed 
developed country–developing country 
pairs, some merged, and researchers, 
teachers, and students moved regularly 
between both settings. The net ﬂ ow 
was to the developing world, with the 
90:10 divide beginning to correct itself 
surprisingly rapidly. Big investments 
in information and communication 
technology meant that those in 
developing countries had the same 
access to information and modern 
learning methods as those in developed 
countries.
The networks of institutions 
developed a global governance 
structure with substantial input from 
politicians, practitioners, policy makers, 
the public, and patients. Academic 
medicine moved from being marginal 
to central in global affairs, and medical 
academics, particularly those with 
experience in both the developing 
and developed world, became global 
leaders. It was a development that 
happened naturally because of their 
broad interests in human rights, justice, 
and the environment.
The “Global Academic Partnership” 
scenario for academic medicine, 
however, was idealistic and sometimes 
Box 4. Common Features 
Shared By All Five Scenarios
• It is likely to be important in all scenarios 
for academic medicine to put more 
effort into relating to its stakeholders: the 
public, patients, practitioners, politicians, 
and policy makers. This may demand the 
development of new institutions that 
involve all these groups.
• Academic institutions will need to be 
more globally minded.
• Teaching, researching, improving, 
leading, and providing service will 
continue to be important, but expecting 
individuals to be competent in them all 
will be increasingly impractical.
• Teamwork will become ever more 
important, but it will also be necessary to 
allow individuals to shine and ﬂ ourish.
• Competition among academic 
institutions is likely to increase, and 
the competition will increasingly be 
international.
• Academic institutions will need to 
become more “business-like” in all the 
scenarios. They will also need to be more 
adept at using the media.
• Teaching and learning will be 
increasingly important—not least 
because dissatisﬁ ed students may go 
elsewhere. Learning will be lifelong 
and will depend heavily on information 
technology.
• It will be increasingly important to 
combine research, both basic and 
applied, with implementation and 
improvement. The gap between 
knowledge and practice will become 
increasingly intolerable.
• The range of types of academic 
institutions is likely to become 
increasingly diverse, with medical schools 
or academic centres just one form.
• Academic medicine will need to be 
ever broader in its thinking and skill 
set, combining with and learning from 
other disciplines such as economics, law, 
ecology, and humanities.
• Thinking about the future will become 
increasingly important for academic 
institutions but also increasingly difﬁ cult.
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struggled with realising its full 
potential—despite the best intentions 
of its architects and practitioners—
because it required enormous political 
will and global cooperation. Too often 
nations would revert to narrow self 
interest. Academics as well often longed 
for the comforts of the developed 
world and sometimes felt exhausted by 
extensive travelling and the enormous 
problems of the developing world.
Fully engaged: “Academic 
medicine engages energetically with 
all stakeholders”. Early in the new 
millennium academic medicine became 
concerned that its relationships with 
its stakeholders were mostly poor. The 
public had little or no understanding 
of what academic medicine was or 
why it mattered. Its very name implied 
irrelevance to many. Patients often felt 
patronised by academics, and many 
practitioners—including doctors—were 
unconvinced of the value of academic 
medicine. “I wouldn’t want a professor 
of surgery touching me,” was a 
commonly heard refrain. Although 
some leading academics did have good 
relationships with politicians, policy 
makers found that many academics 
were not interested in policy problems 
and that the studies they produced, 
even if relevant, came too late to be 
useful. Policy makers recognised that 
biotechnology might be very important 
in future wealth creation, but it was 
difﬁ cult to fund because the public 
proﬁ le of academic medicine was both 
low and clouded.
Most medical academics recognised 
that they were doing a poor job of 
relating to stakeholders and that it 
was thus unsurprising that they were 
misunderstood, underappreciated, and 
seen as largely irrelevant. This, they 
thought, was particularly unfortunate 
as the ability of the system of health 
care to discover, think, study, learn, 
and evaluate had never been more 
important.
The medical academic community 
thus decided that it had to do better, 
and across the globe medical academics 
organised themselves to engage fully 
with their stakeholders. In many 
countries this meant the creation 
of new organisations. In others it 
involved the transformation of existing 
organisations: the gongs and gowns 
were abandoned, and focus groups 
began. Fifty prestigious universities 
in developed countries with medical 
faculties partnered with universities 
in developing countries to help stop 
the “brain drain” and replace it with 
a “brain gain” through incentive 
programs that provided resources 
for training and research, academic 
recognition, travel funds, and family 
support. Everywhere medical academics 
had to learn how to communicate 
with the public, patients, and 
practitioners. They had to stop being 
elitist and patronising and recognise 
the messiness of public discourse. 
Crucially, they had to be much cleverer 
in handling the media, telling them 
not only about their successes but 
also sharing their uncertainties and 
problems.
But communication on its own 
wasn’t enough. Academic medicine 
had to bring its stakeholders inside 
its processes. The governance 
of academies included patients, 
the public, practitioners, health 
administrators, and policy makers. 
Sometimes the president of an academy 
was not a distinguished researcher 
but a prominent patient, journalist, 
or community organisation leader. 
The medical academics discovered 
that their arguments were taken much 
more seriously when advanced clearly 
by a patient rather than by themselves. 
Patients, health administrators, 
and community organisation 
representatives became involved not 
only in peer review of grants and 
studies but also in the prioritising, 
designing, and conducting of research. 
Medical students became the main 
drivers of medical education rather 
than simply its consumers.
Slowly but surely medical academics 
became not a group apart but a 
highly diverse group of people with a 
broad set of skills and backgrounds. 
They were at the centre of a vibrant 
community of patients, members of 
the public, practitioners of all stripes, 
policy makers, members of the media, 
marketing experts, and politicians, all 
of whom were interested in learning, 
studying, researching, and thinking 
about health care. 
Some academics, it must be said, 
found the change uncomfortable 
and were unconvinced of its value. 
Critics talked of “dumbing down” 
and popularisation. They fretted that 
in abandoning its elitism academic 
medicine had lost its ability to be truly 
original and speak independently.
For most, however, academic 
medicine was so much more fun than 
it used to be. Applications to medical 
schools increased. Health services 
invested more in evaluating what they 
did and paid more attention to the 
results. More funds ﬂ owed into basic 
research, and there were improvements 
in the connections between the many 
diverse groups involved in research—
with the result that intellectual silos 
were breached.
Lessons from the Scenarios
None of these scenarios will come to 
exist as we have described them, but 
the future is likely to contain some 
elements from each of them. We have 
tried to identify common features in 
the scenarios to learn lessons for now. 
These features are shown in Box 4. 
Our main hope for these scenarios is 
that other groups may ﬁ nd them useful 
in thinking about both the present 
and the future of academic medicine. 
The scenarios will need to be adapted 
to the particular social, economic, 
and political conditions of different 
regional and national settings. As such, 
they are tools that can be used globally, 
modiﬁ ed as required. We seek not 
agreement but broader thinking. 
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